[{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905 602 5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman of the Board", "fiscalYear": 2023, "totalPay": 85198, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 322408, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hamed  Ghanei", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.0, "open": 9.91, "dayLow": 9.85, "dayHigh": 10.0, "regularMarketPreviousClose": 10.0, "regularMarketOpen": 9.91, "regularMarketDayLow": 9.85, "regularMarketDayHigh": 10.0, "beta": 1.174, "trailingPE": 15.888889, "forwardPE": 20.02, "volume": 2050, "regularMarketVolume": 2050, "averageVolume": 31248, "averageVolume10days": 26640, "averageDailyVolume10Day": 26640, "bid": 10.02, "ask": 10.05, "bidSize": 40000, "askSize": 40000, "marketCap": 256208960, "fiftyTwoWeekLow": 4.14, "fiftyTwoWeekHigh": 14.6, "priceToSalesTrailing12Months": 9.682512, "fiftyDayAverage": 11.0458, "twoHundredDayAverage": 8.64225, "currency": "USD", "enterpriseValue": 287429568, "profitMargins": 0.59922004, "floatShares": 14493609, "sharesOutstanding": 25589500, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.42001, "heldPercentInstitutions": 0.01505, "shortRatio": 0.97, "impliedSharesOutstanding": 25595300, "bookValue": 3.863, "priceToBook": 2.5912504, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.96, "netIncomeToCommon": 15856000, "trailingEps": 0.63, "forwardEps": 0.5, "enterpriseToRevenue": 10.862, "enterpriseToEbitda": 22.861, "52WeekChange": 1.1434689, "SandP52WeekChange": 0.2764505, "exchange": "OQX", "quoteType": "EQUITY", "symbol": "CPHRF", "underlyingSymbol": "CPHRF", "shortName": "Cipher Pharmaceuticals, Inc.", "longName": "Cipher Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1138890600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "33ee6a68-9bd5-3305-98c7-75445d99f34d", "messageBoardId": "finmb_8201659", "gmtOffSetMilliseconds": -18000000, "currentPrice": 10.01, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 9524000, "totalCashPerShare": 0.372, "ebitda": 12573000, "totalDebt": 40752000, "quickRatio": 1.567, "currentRatio": 2.003, "totalRevenue": 26461000, "debtToEquity": 41.223, "revenuePerShare": 1.085, "returnOnAssets": 0.05055, "returnOnEquity": 0.17977, "freeCashflow": -78524128, "operatingCashflow": 13078000, "earningsGrowth": -0.963, "revenueGrowth": 0.709, "grossMargins": 0.80779, "ebitdaMargins": 0.47515, "operatingMargins": 0.18033001, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]